Cargando…

Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report

Aims: Brugada syndrome (BrS) is an inherited cardiac arrhythmia with an increased risk for sudden cardiac death (SCD). About 20% of BrS cases are explained by mutations in the SCN5A gene, encoding the main cardiac sodium Na(v)1.5 channel. Here we present a severe case of cardiac sodium channelopathy...

Descripción completa

Detalles Bibliográficos
Autores principales: Nijak, Aleksandra, Labro, Alain J., De Wilde, Hans, Dewals, Wendy, Peigneur, Steve, Tytgat, Jan, Snyders, Dirk, Sieliwonczyk, Ewa, Simons, Eline, Van Craenenbroeck, Emeline, Schepers, Dorien, Van Laer, Lut, Saenen, Johan, Loeys, Bart, Alaerts, Maaike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396896/
https://www.ncbi.nlm.nih.gov/pubmed/32850980
http://dx.doi.org/10.3389/fcvm.2020.00117
_version_ 1783565663640485888
author Nijak, Aleksandra
Labro, Alain J.
De Wilde, Hans
Dewals, Wendy
Peigneur, Steve
Tytgat, Jan
Snyders, Dirk
Sieliwonczyk, Ewa
Simons, Eline
Van Craenenbroeck, Emeline
Schepers, Dorien
Van Laer, Lut
Saenen, Johan
Loeys, Bart
Alaerts, Maaike
author_facet Nijak, Aleksandra
Labro, Alain J.
De Wilde, Hans
Dewals, Wendy
Peigneur, Steve
Tytgat, Jan
Snyders, Dirk
Sieliwonczyk, Ewa
Simons, Eline
Van Craenenbroeck, Emeline
Schepers, Dorien
Van Laer, Lut
Saenen, Johan
Loeys, Bart
Alaerts, Maaike
author_sort Nijak, Aleksandra
collection PubMed
description Aims: Brugada syndrome (BrS) is an inherited cardiac arrhythmia with an increased risk for sudden cardiac death (SCD). About 20% of BrS cases are explained by mutations in the SCN5A gene, encoding the main cardiac sodium Na(v)1.5 channel. Here we present a severe case of cardiac sodium channelopathy with BrS caused by SCN5A compound heterozygous mutations. We performed a genetic analysis of SCN5A in a male proband who collapsed during cycling at the age of 2 years. Because of atrial standstill, he received a pacemaker, and at the age of 3 years, he experienced a collapse anew with left-sided brain stroke. A later ECG taken during a fever unmasked a characteristic BrS type-1 pattern. The functional effect of the detected genetic variants was investigated. Methods and Results: Next-generation sequencing allowed the detection of two SCN5A variants in trans: c.4813+3_4813+6dupGGGT—a Belgian founder mutation—and c.4711 T>C, p.Phe1571Leu. A familial segregation analysis showed the presence of the founder mutation in the proband's affected father and paternal aunt and the de novo occurrence of the p.Phe1571Leu. The functional effect of the founder mutation was previously described as a loss-of-function. We performed a functional analysis of the p.Phe571Leu variant in HEK293 cells alone or co-expressed with the β(1)-subunit. Compared to the SCN5A wild type, p.Phe1571Leu displayed a hyperpolarizing shift in the voltage dependence of inactivation (loss-of-function), while the activation parameters were unaffected. Using the peptide toxin nemertide α-1, the variant's loss-of-function effect could be restored due to a toxin-dependent reduction of channel inactivation. Conclusion: This is the first report providing support for the pathogenicity of the p.Phe1571Leu SCN5A variant which, together with the c.4813+3_4813+6dupGGGT founder mutation, explains the severity of the phenotype of cardiac sodium channelopathy with BrS in the presented case.
format Online
Article
Text
id pubmed-7396896
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73968962020-08-25 Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report Nijak, Aleksandra Labro, Alain J. De Wilde, Hans Dewals, Wendy Peigneur, Steve Tytgat, Jan Snyders, Dirk Sieliwonczyk, Ewa Simons, Eline Van Craenenbroeck, Emeline Schepers, Dorien Van Laer, Lut Saenen, Johan Loeys, Bart Alaerts, Maaike Front Cardiovasc Med Cardiovascular Medicine Aims: Brugada syndrome (BrS) is an inherited cardiac arrhythmia with an increased risk for sudden cardiac death (SCD). About 20% of BrS cases are explained by mutations in the SCN5A gene, encoding the main cardiac sodium Na(v)1.5 channel. Here we present a severe case of cardiac sodium channelopathy with BrS caused by SCN5A compound heterozygous mutations. We performed a genetic analysis of SCN5A in a male proband who collapsed during cycling at the age of 2 years. Because of atrial standstill, he received a pacemaker, and at the age of 3 years, he experienced a collapse anew with left-sided brain stroke. A later ECG taken during a fever unmasked a characteristic BrS type-1 pattern. The functional effect of the detected genetic variants was investigated. Methods and Results: Next-generation sequencing allowed the detection of two SCN5A variants in trans: c.4813+3_4813+6dupGGGT—a Belgian founder mutation—and c.4711 T>C, p.Phe1571Leu. A familial segregation analysis showed the presence of the founder mutation in the proband's affected father and paternal aunt and the de novo occurrence of the p.Phe1571Leu. The functional effect of the founder mutation was previously described as a loss-of-function. We performed a functional analysis of the p.Phe571Leu variant in HEK293 cells alone or co-expressed with the β(1)-subunit. Compared to the SCN5A wild type, p.Phe1571Leu displayed a hyperpolarizing shift in the voltage dependence of inactivation (loss-of-function), while the activation parameters were unaffected. Using the peptide toxin nemertide α-1, the variant's loss-of-function effect could be restored due to a toxin-dependent reduction of channel inactivation. Conclusion: This is the first report providing support for the pathogenicity of the p.Phe1571Leu SCN5A variant which, together with the c.4813+3_4813+6dupGGGT founder mutation, explains the severity of the phenotype of cardiac sodium channelopathy with BrS in the presented case. Frontiers Media S.A. 2020-07-24 /pmc/articles/PMC7396896/ /pubmed/32850980 http://dx.doi.org/10.3389/fcvm.2020.00117 Text en Copyright © 2020 Nijak, Labro, De Wilde, Dewals, Peigneur, Tytgat, Snyders, Sieliwonczyk, Simons, Van Craenenbroeck, Schepers, Van Laer, Saenen, Loeys and Alaerts. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Nijak, Aleksandra
Labro, Alain J.
De Wilde, Hans
Dewals, Wendy
Peigneur, Steve
Tytgat, Jan
Snyders, Dirk
Sieliwonczyk, Ewa
Simons, Eline
Van Craenenbroeck, Emeline
Schepers, Dorien
Van Laer, Lut
Saenen, Johan
Loeys, Bart
Alaerts, Maaike
Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report
title Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report
title_full Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report
title_fullStr Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report
title_full_unstemmed Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report
title_short Compound Heterozygous SCN5A Mutations in Severe Sodium Channelopathy With Brugada Syndrome: A Case Report
title_sort compound heterozygous scn5a mutations in severe sodium channelopathy with brugada syndrome: a case report
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396896/
https://www.ncbi.nlm.nih.gov/pubmed/32850980
http://dx.doi.org/10.3389/fcvm.2020.00117
work_keys_str_mv AT nijakaleksandra compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT labroalainj compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT dewildehans compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT dewalswendy compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT peigneursteve compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT tytgatjan compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT snydersdirk compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT sieliwonczykewa compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT simonseline compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT vancraenenbroeckemeline compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT schepersdorien compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT vanlaerlut compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT saenenjohan compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT loeysbart compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport
AT alaertsmaaike compoundheterozygousscn5amutationsinseveresodiumchannelopathywithbrugadasyndromeacasereport